May 19, 2021 / 02:55PM GMT
Luca Issi - RBC Capital Markets, Research Division - Research Analyst
Well, great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Markets. And today is our great privilege to have Beth Hougen, the CFO of Ionis for a fireside chat. Thanks so much for joining us. How are you doing today?
Elizabeth L. Hougen - Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Great. Thanks for having this, Luca. I appreciate it.
Questions and Answers:
Luca Issi - RBC Capital Markets, Research Division - Research AnalystThat's fantastic. So can you maybe start with a question on Akcea. You obviously recently completed the acquisition of Akcea. Can you remind us the rationale behind that decision? And maybe just give us a quick update on the process? And how should we think about cost synergies going forward here?
Elizabeth L. Hougen - Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Sure.
Trustpilot
